Europe’s drugs regulator is reviewing possible links between blood clots and Johnson & Johnson’s coronavirus vaccine.
It comes after four serious cases of rare clots with low platelets were reported after inoculation, one of which was fatal said a statement from the European Medicines Agency (EMA).
The Johnson & Johnson (also known as Janssen) vaccine has been rolled out in the European Union and the US in recent months, having proved 67% effective in preventing COVID-19 and completely effective at preventing hospital admissions and death from the virus during trials.
It stands out from the other jabs being used because only one shot is needed, rather than two.
The UK has ordered 30 million doses, but it has not yet been approved by the regulator.